152 related articles for article (PubMed ID: 38617922)
1. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
Oki JC
Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
[TBL] [Abstract][Full Text] [Related]
2. Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits.
Yaribeygi H; Maleki M; Rashid-Farrokhi F; Abdullahi PR; Hemmati MA; Jamialahmadi T; Sahebkar A
Heliyon; 2024 Apr; 10(7):e28837. PubMed ID: 38617922
[TBL] [Abstract][Full Text] [Related]
3. The Beneficial Effects of Curcumin on Lipids: Possible Effects on Dyslipidemia-Induced Cardiovascular Complications.
Yaribeygi H; Maleki M; Butler AE; Jamialahmadi T; Gumpricht E; Sahebkar A
Curr Med Chem; 2023 Jul; ():. PubMed ID: 37424347
[TBL] [Abstract][Full Text] [Related]
4. Crocin inhibits obesity via AMPK-dependent inhibition of adipocyte differentiation and promotion of lipolysis.
Gu M; Luo L; Fang K
Biosci Trends; 2018; 12(6):587-594. PubMed ID: 30674760
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of crocin and voluntary exercise against oxidative stress in the heart of high-fat diet-induced type 2 diabetic rats.
Ghorbanzadeh V; Mohammadi M; Mohaddes G; Dariushnejad H; Chodari L; Mohammadi S
Physiol Int; 2016 Dec; 103(4):459-468. PubMed ID: 28229629
[TBL] [Abstract][Full Text] [Related]
6. Crocin-I ameliorates the disruption of lipid metabolism and dysbiosis of the gut microbiota induced by chronic corticosterone in mice.
Xie X; Xiao Q; Xiong Z; Yu C; Zhou J; Fu Z
Food Funct; 2019 Oct; 10(10):6779-6791. PubMed ID: 31576875
[TBL] [Abstract][Full Text] [Related]
7. Effective Therapeutic Verification of Crocin I, Geniposide, and Gardenia (
Zhou H; Zhang S; Chen L; Liu Y; Shen L; Zhang J
Foods; 2023 Apr; 12(8):. PubMed ID: 37107463
[TBL] [Abstract][Full Text] [Related]
8. The effects of phytochemicals on serum triglycerides in subjects with hypertriglyceridemia: A systematic review of randomized controlled trials.
Dadkhah Tehrani S; Shojaei M; Bagherniya M; Pirro M; Sahebkar A
Phytother Res; 2023 Apr; 37(4):1640-1662. PubMed ID: 36756995
[TBL] [Abstract][Full Text] [Related]
9. 2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.
Banach M; Reiner Z; Cicero AFG; Sabouret P; Viigimaa M; Sahebkar A; Postadzhiyan A; Gaita D; Pella D; Penson PE
Arch Med Sci; 2022; 18(6):1429-1434. PubMed ID: 36457968
[No Abstract] [Full Text] [Related]
10. Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu.
Yaribeygi H; Maleki M; Reiner Ž; Jamialahmadi T; Sahebkar A
J Clin Med; 2022 Nov; 11(21):. PubMed ID: 36362772
[TBL] [Abstract][Full Text] [Related]
11. Effect of crocin on glycated human low-density lipoprotein: A protective and mechanistic approach.
Wani MJ; Salman KA; Moin S; Arif A
Spectrochim Acta A Mol Biomol Spectrosc; 2023 Feb; 286():121958. PubMed ID: 36244155
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial.
Jaafarinia A; Kafami B; Sahebnasagh A; Saghafi F
BMC Complement Med Ther; 2022 Oct; 22(1):262. PubMed ID: 36209091
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced nephrotoxicity was improved by crocin in mouse model.
Yin Q; Xiong H
Eur J Histochem; 2022 Oct; 66(4):. PubMed ID: 36190398
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
